PRESS RELEASE published on 06/03/2024 at 07:30, 3 months 16 days ago Informations privilégiées / Autres communiqués GenSight Biologics nomme William Monteith à son Conseil d'administration. Monteith apportera son expertise en fabrication de thérapies géniques pour soutenir les progrès de l'entreprise Conseil D'administration Fabrication GenSight Biologics Thérapies Géniques William Monteith
BRIEF published on 05/23/2024 at 11:40, 3 months 27 days ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
BRIEF published on 05/23/2024 at 11:40, 3 months 27 days ago Franchissement de seuils pour GENSIGHT BIOLOGICS S.A. Actions Franchissement De Seuils Bons De Souscription GenSight Biologics Armistice Capital
PRESS RELEASE published on 05/23/2024 at 11:35, 3 months 27 days ago Franchissement de seuils Déclaration de franchissement de seuils par Armistice Capital, LLC concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils Armistice Capital LLC GENSIGHT BIOLOGICS SA Déclaration Régularisation
BRIEF published on 05/07/2024 at 19:34, 4 months 12 days ago GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris Euronext Paris Capital Increase Gene Therapy Prospectus GenSight Biologics
BRIEF published on 05/07/2024 at 19:34, 4 months 12 days ago GenSight Biologics annonce la mise à disposition d'un prospectus pour la cotation de nouvelles actions sur Euronext Paris Euronext Paris Augmentation De Capital Thérapie Génique Prospectus Produits Biologiques GenSight
PRESS RELEASE published on 05/07/2024 at 19:29, 4 months 12 days ago Modalités de mise à disposition de prospectus GenSight Biologics annonce la mise à disposition d'un prospectus pour l'admission d'actions nouvelles sur Euronext Paris. La société spécialisée dans les thérapies géniques pour les maladies neurodégénératives informe sur le processus Euronext Paris Prospectus GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
PRESS RELEASE published on 05/07/2024 at 19:29, 4 months 12 days ago Terms of availability of prospectuses GenSight Biologics announces availability of listing prospectus for new shares on Euronext Paris. The prospectus approved by AMF includes universal registration document, securities note, and summary Euronext Paris New Shares AMF Approval GenSight Biologics Listing Prospectus
Published on 09/19/2024 at 23:15, 28 minutes ago Cypher Metaverse Inc. Announces Second Closing of Financing
Published on 09/19/2024 at 23:00, 43 minutes ago WestJet Partners with FLYHT and NOAA to Improve Weather Forecasting in North America
Published on 09/19/2024 at 20:15, 3 hours 28 minutes ago Living Security Named a Leader in Human Risk Management, Closely Watched Tech Industry Report
Published on 09/19/2024 at 21:09, 2 hours 33 minutes ago EQS-Adhoc: Mercedes-Benz Group AG adjusts full-year guidance for the year 2024 based on current market outlook
Published on 09/19/2024 at 18:44, 4 hours 59 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/19/2024 at 18:03, 5 hours 40 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 09/19/2024 at 17:52, 5 hours 51 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 5 hours 51 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:45, 5 hours 58 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 5 hours 58 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 5 hours 58 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)